The folate biosynthetic pathway and its key enzyme dihydrofolate reductase (DHFR) is a popular target for drug development due to its essential role in the synthesis of DNA precursors and some amino acids. Despite its importance, little is known about plant DHFRs, which, like the enzymes from the malarial parasite Plasmodium, are bifunctional, possessing DHFR and thymidylate synthase (TS) domains. Here using genetic knockout lines we confirmed that either DHFR-TS1 or DHFR-TS2 (but not DHFR-TS3) was essential for seed development. Screening mutated Arabidopsis thaliana seeds for resistance to antimalarial DHFRinhibitor drugs pyrimethamine and cycloguanil identified causal lesions in DHFR-TS1 and DHFR-TS2, respectively, near the predicted substrate-binding site. The different drug resistance profiles for the plants, enabled by the G137D mutation in DHFR-TS1 and the A71V mutation in DHFR-TS2, were consistent with biochemical studies using recombinant proteins and could be explained by structural models. These findings provide a great improvement in our understanding of plant DHFR-TS and suggest how plant-specific inhibitors might be developed, as DHFR is not currently targeted by commercial herbicides.
INTRODUCTION
The folate biosynthetic pathway provides essential cofactors involved in one-carbon transfer reactions. These cofactors, tetrahydrofolate and its derivatives (collectively termed folates) play a crucial role in the synthesis of purines and thymidylate, amino acids (methionine, serine and glycine), pantothenate (vitamin B 5 ) and formyl methionyltRNA (Sahr et al., 2005; Hanson and Gregory, 2011) . Humans and other animals cannot synthesize folates de novo, and rely on their diets for folate intake (Hossain et al., 2004) . The chemical structure of tetrahydrofolate (THF) consists of a reduced pterin group, a p-aminobenzoyl unit and a glutamate moiety, to which additional glutamate residues are typically linked. The level of polyglutamylation of THF is suggested to play a role in its cellular transport (i.e. monoglutamylated) or interaction with folate-dependent enzymes (i.e. preferentially polyglutamylated). Depending on its oxidation state, one-carbon units are enzymatically attached to THF at N 5 and/or N 10 positions, resulting in several forms of folate involved in different enzymatic reactions (Hanson and Gregory, 2002; Figure 1a) . In plant cells, folate metabolism occurs throughout different compartments, i.e. in the cytosol, the chloroplasts and the mitochondria. As such, the synthesis of the different folate units, the expression and localisation of the folate enzymes, and the transport of folates inside the cell must be tightly regulated (Hanson and Gregory, 2011) .
Dihydrofolate reductase (DHFR) is ubiquitous, and is found in all organisms where it catalyses the reduction of dihydrofolate (DHF) into THF using NADPH as the reducing agent (Askari and Krajinovic, 2010; Figure 1a) . The first reported DHFR crystal structure was from Escherichia coli and solved as a complex with methotrexate (Matthews et al., 1977) . Since then, over 400 DHFR crystal structures from different organisms have been submitted to Protein Data Bank (www.rcsb.org), although no plant DHFR structure has been determined. In most prokaryotes and eukaryotes, DHFR is encoded by genes for a monofunctional protein. However, in protozoa and plants, DHFR is encoded by a gene for a bifunctional protein composed of DHFR as one domain, connected to a thymidylate synthase (TS) domain (Cox et al., 1999) . TS also plays an essential role in the folate pathway by catalysing the conversion of deoxyuridine monophosphate to deoxythymidine monophosphate using the methylene form of THF as methyl-group donor and resulting in DHF as by-product (Wilson et al., 2014; Figure 1a) . The bifunctional DHFR-TS genes are organised with the DHFR domain located at the amino-terminus and the TS domain present at the carboxy-terminus, connected by a junction sequence (Lazar et al., 1993) . Having the DHFR and TS domains close together is thought to allow efficient channelling of substrates between both active sites (Metzger et al., 2014) . In the malarial parasite Plasmodium falciparum, its bifunctional DHFR-TS forms a dimer with close contact at the TS domains (Yuthavong et al., 2005; Figure 1b ). Although DHFR is conserved across all kingdoms, pairwise comparisons between the plant DHFR domain and either bacterial, mammalian or protozoan DHFRs typically give matches of 29-35% identity and 46-56% similarity (Figure 1c ).
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DHFR
Due to its critical role, DHFR is the target of several drugs used to treat various pathogens. The diaminopyrimidine drug trimethoprim is an antibacterial agent that inhibits bacterial DHFR (Hawser et al., 2006) . A point mutation that causes a I100L amino acid substitution in the Streptococcus pneumoniae DHFR putative trimethoprim binding site resulted in a 50-fold increase in ID 50 (Adrian and Klugman, 1997) . Resistance to trimethoprim was also found in Staphylococcus aureus carrying a F98Y mutation in its DHFR (Dale et al., 1997) . Pyrimethamine and cycloguanil are known inhibitors of P. falciparum DHFR-TS. A double mutation (A16V and S108T) in P. falciparum DHFR confers resistance to cycloguanil but not to pyrimethamine, whereas single or multiple amino acid mutations at positions 51, 59, 108 and 164 were correlated with cross-resistance to both compounds (Rastelli et al., 2000) . In mammalian cell systems, resistance to methotrexate, a very close analogue of DHF, was correlated with a decrease in uptake and polyglutamylation of the compound as well as increased DHFR gene copy number and translational upregulation of the enzyme, rather than mutation in DHFR (Banerjee et al., 2002) . In Arabidopsis thaliana cells treated with methotrexate, the cellular responses to folate depletion correlated with a major change in the composition of the folate species prioritising the use of available folates towards nucleotide synthesis at the expense of other reactions involved in one-carbon metabolism (Loizeau et al., 2008) . TS has also been investigated as a potential drug target in cancer therapy, whereby inhibitors compete with deoxyuridine monophosphate or the folate-binding site of the enzyme (Chu et al., 2003; Ackland et al., 2006) . In contrast to DHFR, the TS domain displays a higher level of conservation across organisms; the A. thaliana TS domain aligned pairwise to the P. falciparum TS domain or TS from E. coli, human or mouse gives matches of 48-61% identity and 64-73% similarity ( Figure 1c ).
Although it is generally accepted that DHFR-TS acts as a bifunctional enzyme in plants, Maniga et al. (2017) found that alternatively spliced variants of A. thaliana DHFR-TS isoforms (i.e. truncated variants possessing only the DHFR domain) could potentially be expressed. This could suggest a role of these truncated proteins as monofunctional enzymes involved in pathways other than DNA synthesis. The authors also found the three DHFR-TS genes to be expressed in different tissues. DHFR-TS1 was mainly expressed in meristematic and differentiated tissues, with a strong expression in vascular tissues. DHFR-TS2 was expressed primarily in meristematic tissues, underlying a primary role in DNA synthesis in actively dividing cells. On the other hand, the expression of DHFR-TS3 seemed to be specific to the columella and the lateral root cap, and meristematic cells of the shoot apex (Maniga et al., 2017) .
A recent genetic and biochemical study by Gorelova et al. (2017) found DHFR-TS1 and DHFR-TS2 were essential but genetically redundant, and so could not obtain dhfr-ts1 dhfr-ts2 double mutants. They showed that although lossof-function for DHFR-TS3 was possible in dhfr-ts1 and dhfr-ts2 single mutant backgrounds, constitutive overexpression of DHFR-TS3 in CaMV35S transgenic lines reduced folate content and delayed plant development in transgenic lines. Using recombinant enzymes in vitro, DHFR-TS3 was shown to be catalytically inactive itself, but could diminish the activities of DHFR-TS1 or DHFR-TS2 (Gorelova et al., 2017) .
We recently demonstrated that antimalarial drugs, including the antifolates pyrimethamine and cycloguanil, have herbicidal activity against the model plant A. thaliana (Corral et al., 2017a (Corral et al., ,b, 2018 . Given that both pyrimethamine and cycloguanil are known to target the DHFR domain Figure 1 . Part of the folate biosynthesis pathway and dihydrofolate reductase (DHFR) enzymes. (a) DHFR catalyses the reduction of dihydrofolate (DHF) into tetrahydrofolate (THF) using NADPH as the electron donor. The site of reduction is asterisked. The thymidylate synthase (TS) domain catalyses methylation of deoxyuridine monophosphate (dUMP) into deoxythymidine monophosphate (dTMP) using 5,10-CH 2 -THF as reductant and methyl-group donor. p-ABA, p-aminobenzoate; SHMT, serine hydroxymethyltransferase. (b) Protein structures of monofunctional Escherichia coli (PDB 4RGC) and human (PDB 4M6K) DHFR. Bifunctional Plasmodium falciparum and Arabidopsis thaliana DHFR-TS with both DHFR (magenta) and TS (blue) domains. PfDHFR-TS (PDB 4DPD) is displayed as a dimer. DHFR-TS1 (At2g16370) is a homology model and shown as a monomer. (c) Protein sequence alignments of various DHFR domains (top) and TS domains (bottom). Conserved amino acid residues are highlighted in grey and outlined in black.
of Plasmodium DHFR-TS, it is probable that their herbicidal effect is via plant DHFR-TS inhibition. If so, plant DHFR-TS could represent a new molecular target for herbicide development. Of 334 commercial herbicides (Gandy et al., 2015) , only 20 modes-of-action are known and, with the continued emergence of herbicide resistance in weeds (Heap, 2014) , novel modes-of-action need to be considered.
RESULTS
The genome of A. thaliana is annotated to contain three genes for DHFR-TS proteins: DHFR-TS1 (At2g16370), DHFR-TS2 (At4g34570) and DHFR-TS3 (At2g21550). DHFR-TS1 (519 residues) has 87% identity and 94% similarity to DHFR-TS2 (565 residues) when the first 50 residues of DHFR-TS2 are excluded. The N-terminal sequence of DHFR-TS2 is predicted by MitoFates to contain a mitochondrial presequence (probability of 0.922; Fukasawa et al., 2015) . The putative protein encoded by DHFR-TS3 (492 residues) is divergent from the other two gene products, sharing 56% identity and about 75% similarity to either DHFR-TS1 or DHFR-TS2 based on pairwise comparisons ( Figure S1a ).
DHFR-TS1 and DHFR-TS2 are genetically redundant and required for seed development
We obtained and confirmed two T-DNA insertion mutants for each of the three A. thaliana DHFR-TS genes (Figure S1b ). The precise insertion point for each T-DNA was determined by sequencing the polymerase chain reaction (PCR) product amplified when using a primer for the T-DNA left border and a gene-specific primer ( Figure S1c ). For all six T-DNA mutants, the open reading frame was interrupted mostly in exons, with a lack of detectable native mRNA from each interrupted gene confirmed by reverse transcription PCR ( Figure S1d) .
As observed by Gorelova et al. (2017) , we confirmed no single mutant displayed a visible developmental phenotype, and we could obtain homozygous dhfr-ts1 dhfr-ts3 double mutants as well as dhfr-ts2 dhfr-ts3 double mutants. No dhfr-ts1 dhfr-ts2 double mutant was obtained, confirming combination of null alleles for these two genes is lethal. Siliques from a plant homozygous for one gene and heterozygous for the other showed one-quarter seed abortion ( Figure S2 ; Tables 1 and S1 ). These findings were consistent with the previous observations that DHFR-TS1 and DHFR-TS2 are both essential for seed maturation, but functionally redundant (Gorelova et al., 2017) .
While analysing the siliques of dhfr-ts T-DNA mutants, we noticed that the number of seeds in the pods of all heterozygous dhfr-ts2-1 lines was reduced by approximately 50% (Tables 1 and S1 ), indicating a defect in ovule formation. This suggests the dhfr-ts2-1 T-DNA insertion (SALK_016377) was associated with chromosomal rearrangements that create unviable gametes most likely due to abnormal pairing of homologous chromosomes during meiosis only in heterozygous dhfr-ts2-1 backgrounds (Clark and Krysan, 2010) . A high proportion of defective pollen was observed for five different dhfr-ts2-1(+/À) genetic backgrounds, and the siliques of these five lines were significantly smaller than wild-type (WT) or dhfr-ts2 single mutants, consistent with an ovule defect and reduced seed content ( Figure S3 ). Although the homozygous dhfr-ts2-1 mutant is likely to contain a chromosomal rearrangement, these plants displayed no visible phenotypes, had WT proportions of aborted seed ratios and the same susceptibility to antifolates as dhfr-ts2-2 (Figure 2 ; Tables 1 and S1 ).
To explore the previously observed sensitivity to DHFR inhibitors (Corral et al., 2017a) , dhfr-ts single mutant and WT seeds were raised on media containing a range of concentrations for cycloguanil, pyrimethamine, methotrexate or trimethoprim (Figure 2 ). All four compounds were herbicidal, with cycloguanil, pyrimethamine and methotrexate arresting seed germination post-radicle emergence in WT
Genotypes
Total seed count % aborted seeds
50.9 AE 0.7 25.0 AE 1.4
For each genotype, 20 siliques were dissected and seeds (normal versus defective) were counted to provide a ratio of aborted seeds. Values are given as mean AE SE. Refer to Table S1 for a more exhaustive list of genotypes. at 20, 12.5 and 0.1 lg ml À1 respectively, whereas trimethoprim induced yellowing and arrested seedling growth at 30 lg ml À1 . The dhfr-ts1 and dhfr-ts3 single mutants displayed a similar sensitivity to WT, whereas both dhfr-ts2 T-DNA lines (dhfr-ts2-1 and dhfr-ts2-2) displayed an approximately fourfold greater sensitivity to cycloguanil and trimethoprim (Figure 2 ), suggesting that consistent with most folate synthesis thought to be in the mitochondria (Neuburger et al., 1996) and the localisation of DHFR-TS2 likely to be mitochondrial, DHFR-TS2 might have a prevalent role in folate synthesis over DHFR-TS1 in A. thaliana seedlings.
DHFR-TS1 is alternatively spliced in mature leaves
While cloning the full-length DHFR-TS1 from cDNA produced using mature leaf RNA, we found that the encoded protein varied from the protein model At2g16370.1 (519 residues) as it retained intron 7, resulting in an early stop codon. The putative protein encoded by this leaf RNA transcript is truncated to 420 amino acids in length, with the first 406 residues matching At2g16370.1, therefore still retaining the DHFR domain, but disrupting its TS domain. This shorter alternative variant of DHFR-TS1 mRNA is annotated as At2g16370.2, and RNA-sequencing-based evidence analysed at ePlant (Fucile et al., 2011) showed it was present in leaf tissue, but absent in light-grown A. thaliana seedlings. The purpose of this alternative splicing is unclear, and when a BLASTP search was performed against green plants using the 420-residue truncated DHFR-TS1, no conserved truncated DHFR-TS homologues were found, suggesting that the protein model At2g16370.2 might be uniquely found in A. thaliana. Another splice isoform of DHFR-TS1 lacking the TS domain and predicted to be 270 amino acids long was reported by Maniga et al. (2017) . Whether or not these transcript variants encode functional DHFR protein monomers or are transcriptional artefacts that are degraded remains unclear.
Subcellular localisation for tagged DHFR-TS1 and DHFR-TS2 proteins
DHFR-TS2 has a predicted mitochondrial presequence whereas DHFR-TS1 does not, suggesting these genetically redundant proteins occupy different subcellular compartments. To acquire experimental evidence for their localisation, we generated C-terminal green fluorescent protein (GFP) fusions to full-length DHFR-TS1 and DHFR-TS2. These fusion constructs were expressed transiently in A. thaliana cell suspensions along with a red fluorescent protein (RFP) fusion to ALTERNATIVE OXIDASE 1 as a control for mitochondrial localisation (Figures 3a and b , and S4). The C-terminal GFP fusion to DHFR-TS1 was targeted to the cytoplasm, consistent with previous experimental evidence of a cytoplasmic location (Ito et al., 2011) . To confirm that the C-terminal GFP tag was not disrupting any targeting signal, we generated an N-terminal GFP fusion to DHFR-TS1 and observed it also localised in the cytoplasm ( Figure S4 ). By contrast, the localisation of a C-terminal GFP fusion to DHFR-TS2 was shown to be predominantly to the mitochondria consistent with its predicted mitochondrial presequence. A mitochondrial localisation for DHFR-TS2 is also consistent with previous experimental mass spectrometry evidence identifying DHFR-TS2 as located in the mitochondrion (Senkler et al., 2017) . To complement these findings, we performed in vitro import assays with isolated mitochondria using established methods (Duncan et al., 2015; Murcha and Whelan, 2015) and radiolabelled DHFR-TS1 and DHFR-TS2 ( Figure 3c ). The DHFR-TS2 precursor and positive control ALTERNATIVE OXIDASE 1 (AOX1) both exhibited import and processing to smaller, mature forms, whereas the DHFR-TS1 protein displayed no import or processing in these assays. Proteinase K was used to digest any protein that did not import into the mitochondria, and valinomycin was used to block import into mitochondria. Taken together, the evidence suggests that DHFR-TS1 and DHFR-TS2 reside predominantly in different subcellular compartments.
DHFR point mutations provide antifolate drug resistance
The antimalarial drugs pyrimethamine and cycloguanil are DHFR inhibitors that, along with other antifolates, have been shown to be herbicidal (Corral et al., 2017a) . To confirm both drugs also act through plant DHFR-TS inhibition, we screened mutagenised A. thaliana seeds for resistance to either compound. The pyrimethamine screen produced two resistant mutants, and sequencing of their DHFR-TS genes identified the same G to A change that causes a Gly to Asp substitution at residue 137 in the protein encoded by DHFR-TS1. The cycloguanil screen produced a single resistant mutant, and sequencing its candidate genes identified a C to T lesion that caused an Ala to Val change at residue 71 in the protein encoded by DHFR-TS2 ( Figure S1a ). Backcrossing resistant M 3 mutants to WT revealed the drug resistance provided by these lesions was genetically dominant. The pyrimethamine-resistant G137D allele of DHFR-TS1 was named dhfrts1-4, and the cycloguanil-resistant A71V allele of DHFR-TS2 was named dhfr-ts2-3 (Figure 4a ). Both lesions are in the DHFR domain, close to the binding sites for DHF (Figure 4b ).
To confirm the lesions were causal, as resistance was genetically dominant, drug-susceptible WT A. thaliana was transformed with the mutant DHFR-TS1 or DHFR-TS2 gene and tested for drug resistance. A region of DHFR-TS1 genomic DNA was amplified by PCR from dhfr-ts1-4 and transformed into WT A. thaliana, and the transgenic lines tested for conferral of resistance to pyrimethamine. As expected, the dhfr-ts1-4-derived transgene conferred resistance to pyrimethamine and also to other DHFR drugs, including cycloguanil, trimethoprim and methotrexate ( Figure 5 ). Similarly, a DHFR-TS2 transgene from the dhfr-ts2-3 mutant conferred cycloguanil resistance upon the transformed WT background. The dhfr-ts2-3 transgene, however, did not confer resistance to pyrimethamine and provided little protection against trimethoprim and methotrexate ( Figure 5 ). These data confirm the causality of the point mutations and suggest, depending on the mutation, that broad or specific resistance to DHFR inhibitors is conferred.
Sites of drug resistances at the DHFR active site
To elucidate a structural basis for the difference in resistance profiles to DHFR inhibitors of the G137D and A71V mutants in DHFR-TS1 and DHFR-TS2, respectively, we modelled the structure of A. thaliana DHFR-TS1 and DHFR-TS2 using the crystal structure of protozoan Babesia bovis DHFR-TS (Begley et al., 2011) as it shares~43% sequence similarity ( Figure 4b ). The predicted structures suggest both DHFR-TS1 and DHFR-TS2 form canonical bifunctional DHFR-TS enzymes whereby the DHFR domains (residues 21-198 and 64-242, respectively) form an eight-stranded b-sheet encased by four short a-helical regions, linked to a C-terminal TS domain (residues 223-519 and 271-565, respectively) by a long Class I type junctional region that has been shown to join adjacent DHFR monomers (O'Neil et al., 2003) . Moreover, the TS domains both exhibit a highly conserved active site surrounded by a-helices and oriented away from a potential b-stranded dimerisation interface. Alignment of our models to the crystal structure of a bifunctional DHFR-TS enzyme from Cryptosporidium hominis (O'Neil et al., 2003) in complex with the ligands DHF and NADPH revealed both mutations were in the DHFR domain, with the DHFR-TS1 G137D mutation close to the phosphate backbone of the NADPH cofactor. The DHFR-TS2 A71V mutation was located close to the pterinyl moiety of the DHF substrate ( Figure 4b ). The predicted close vicinity of these residues to the substrate and cofactor binding sites, which are commonly targeted by antimalarial inhibitors, provided further evidence that these mutations were responsible for the resistance to herbicidal antimalarial compounds.
Recombinant DHFR-TS1 and DHFR-TS2 mutants showed antifolate resistance in vitro
Target-based resistance to herbicides often comes with a fitness penalty (Roux et al., 2004 (Roux et al., , 2005 , but, consistent with Gorelova et al. (2017) , we observed the dhfr-ts1-4 and dhfr-ts2-3 single mutations appeared to have no obvious effect on plant phenotype. To determine whether either enzyme was subject to a decrease in biochemical activity due to their genetic mutations, we purified recombinant A. thaliana DHFR-TS1 and DHFR-TS2 from E. coli ( Figure S5 ) and conducted DHFR activity assays by measuring the A 340 decrease as NADPH is oxidised during DHF reduction to THF (Figures 6, S5 and S6) . This was compared with the activity of recombinant DHFR-TS1 with the G137D mutation (DHFR-TS1-G137D) and DHFR-TS2 with the A71V mutation (DHFR-TS2-A71V). The G137 that is mutated to aspartic acid in DHFR-TS1 and confers pyrimethamine resistance has an equivalent residue in DHFR-TS2 (G181). Similarly, the A71 residue mutated to valine in DHFR-TS2 has an equivalent residue in DHFR-TS1 (A27; Figure S6 ). To establish whether the equivalent mutation can provide drug resistance in both DHFR-TS proteins, reciprocal mutations were made. In the absence of inhibitors, the activity of all the mutated recombinant enzymes was lower than its WT. The (b) Predicted models of dihydrofolate reductase (DHFR)-thymidylate synthase (TS)1 and DHFR-TS2 active sites showing residues involved in resistance to DHFR inhibitors. Wild-type (WT) DHFR-TS1 and DHFR-TS2 active sites (top) in complex with substrate DHF (green) and cofactor NADPH (dark blue). The WT residues that mutate to give resistance are shown as black sticks. The dhfr-ts1-4 active site complexed with pyrimethamine (yellow sticks) and NADPH. Asp137 mutation (magenta) is the in vivo causative lesion responsible for pyrimethamine resistance and cross-resistance to other antifolates. Val27 mutation (magenta) was created in vitro and corresponds to the equivalent Val71 mutation found in DHFR-TS2. The dhfr-ts2-3 active site complexed with cycloguanil (cyan) and NADPH. The Val71 mutation (magenta) confers resistance to cycloguanil, but not pyrimethamine. Asp181 (magenta) was mutated in vitro and is equivalent to the DHFR-TS1 Asp137 mutation.
A71V mutation in DHFR-TS2 and its equivalent A27V mutation in DHFR-TS1 induced a decrease in DHFR activity of about 35% when compared with WT. The G137D mutation in DHFR-TS1 and its reciprocal lesion G181D in DHFR-TS2 induced a decrease in activity of~75-85%, respectively ( Figure 6 ).
In the presence of cycloguanil or pyrimethamine, the protective effect of the mutations became apparent. The activity of WT DHFR-TS1 and DHFR-TS2 in 2 lM of either drug was abolished. In contrast, both enzymes with the Ala to Val mutation remained active in the presence of cycloguanil with a decrease of 60-65% activity. However, the Ala to Val mutation provided no protection from pyrimethamine. The activity of both enzymes with the Gly to Asp mutation continued in the presence of cycloguanil or pyrimethamine. The activity of DHFR-TS1 G137D was not affected by either drug, whereas DHFR-TS2 G181D remained active, but had a decrease of approximately 40% in activity when challenged by either drug (Figure 6 ). These data demonstrated that the mutations do decrease enzyme activity, but protect the enzymes from inhibitors in a manner consistent with the in planta results. Notably, the Ala to Val change provides resistance to cycloguanil, but not pyrimethamine, whereas the Gly to Asp change provides cross-resistance to both inhibitors.
DISCUSSION
Folates are essential to all organisms, and serve as cofactors by donating one-carbon units in enzymatic reactions involved in the synthesis of nucleic acids, vitamins and amino acids, among others. The last step in the folate pathway is the reduction of DHF into THF using NADPH as (c) Example of derived cleaved amplified polymorphic sequences (dCAPS) analysis used to track the G137D mutation in DHFR-TS1. Polymerase chain reaction (PCR) products amplified from WT, dhfr-ts1-4 (M 3 parent bearing G137D mutation in DHFR-TS1) and DHFR-TS1 G137D lines were digested with BstEII and run on a 4.5% agarose gel. The WT sequence is cleaved, whereas the mutant amplicon is not. (d) Chemical structure of DHF and the DHFR inhibitors cycloguanil, pyrimethamine, trimethoprim and methotrexate.
hydrogen donor, a reaction catalysed by dihydrofolate reductase (DHFR; Figure 1a ). As the maintenance of cellular folates must be sustained, DHFR has been extensively studied, and is a drug target for the treatment of tropical diseases, bacterial infections and cancer therapies. Although a wealth of data is available for mammalian, bacterial and protozoan DHFR, little is known about this important enzyme in plants. Like protozoans, plants have evolved a gene that encodes a bifunctional enzyme with a DHFR domain and a TS domain, and so is referred to as DHFR-TS. In A. thaliana, three DHFR-TS genes are annotated in its genome: DHFR-TS1 (At2g16370), DHFR-TS2 (At4g34570) and DHFR-TS3 (At2g21550). The purpose of this study was to provide insights into the functional relevance of the A. thaliana DHFR-TS gene products, but also to provide data that could help design plant-specific DHFR inhibitors. Protein sequence alignments revealed that DHFR-TS1 and DHFR-TS2 share a high degree of conservation, and the most substantial difference between the two proteins is the presence of a mitochondrial presequence at the Nterminus of DHFR-TS2. In contrast, DHFR-TS3 seems to have diverged from its counterparts ( Figure S1a ). Our reverse genetics showed that although dhfr-ts1 dhfr-ts3 and dhfr-ts2 dhfr-ts3 double mutants were obtainable, a dhfr-ts1 dhfr-ts2 double mutant was lethal and resulted in aborted seeds (Table 1; Figure S2 ). This was consistent with work by Gorelova et al. (2017) who showed DHFR-TS1 and DHFR-TS2 were essential, but functionally redundant. Similar genetic redundancy for an essential function has also been observed for the A. thaliana folylpolyglutamate synthetases, which are enzymes involved in THF polyglutamylation. For this enzyme family, the cytosolic, mitochondrial and plastidic isoforms displayed functional redundancy based on T-DNA double mutant analyses (Mehrshahi et al., 2010) .
Although A. thaliana has three, the number of DHFR-TS genes in plant species ranges from one in early plants such as Physcomitrella patens and Selaginella moellendorffii to up to five in Zea mays ( Figure S7 ). In silico analysis of the sequences suggests that the cytosolic DHFR-TS is the predominant form, with some species additionally possessing transcripts for DHFR-TS proteins that contain N-terminal extensions predicted to be targeting signals to the mitochondrion and/or chloroplast ( Figure S7 ). It is worth noting that work by Gorelova et al. (2017) suggested GFP-tagged DHFR-TS1 and DHFR-TS2 expressed in roots of A. thaliana localised to different compartments in a root-zone specific manner. DHFR-TS1-GFP was found in the cytosol and nucleus of root meristematic, transition and elongation zone cells. In elongation zone cells, they observed DHFR-TS1-GFP also co-localising to mitochondria. Gorelova et al. (2017) found DHFR-TS2-GFP was mainly observed in the mitochondria and nuclei of root meristematic and transition zone cells, but confined to mitochondria in elongation zone cells. Our localisation studies could not detect DHFR-TS1 in the mitochondria or in the nucleus, and could not detect DHFR-TS2 in the nucleus. Our in vitro mitochondrial import assays were consistent with our . Dihydrofolate reductase (DHFR) activity of recombinant wild-type (WT) and mutated DHFR-thymidylate synthase (TS) enzymes given as mean from three replicates AE SE. Activity of recombinant WT and mutant DHFR-TS1 and DHFR-TS2 in the absence of inhibitor (black) or in the presence of cycloguanil (grey) and pyrimethamine (white) calculated from the NADPH absorbance readings and standard curve ( Figures S5 and S6 ) and given as mU per mg of enzyme. One unit of DHFR is defined as the amount of enzyme that oxidises 1 lmol of NADPH per min at room temperature. Statistical differences were determined using a Student's t-test, and are represented with an asterisk (*P < 0.05 and **P < 0.01) when comparing the DHFR activity of the mutant enzymes with their respective WT enzyme in the absence of inhibitors, or with letters when comparing the DHFR activity of a given recombinant enzyme with or without inhibitors (for both Ala mutants: a/b P < 0.01, a/c P < 0.05). Neither Gly mutant was significantly affected by inhibitors.
tagged GFP findings, but additional localisation of the protein in other compartment(s) cannot be excluded. Despite different subcellular localisation patterns for DHFR-TS1 and DHFR-TS2, the genes are genetically redundant. The hypersensitivity of dhfr-ts2 mutants to DHFR inhibitors (Figure 2 ) and the prevailing view that folate synthesis occurs principally in mitochondria (Hanson and Gregory, 2011) suggests DHFR-TS2 is the major contributor of DHFR activity in seedlings of A. thaliana. This is consistent with a significant decrease in DHFR activity for 3-day-old dhfr-ts2 single mutants compared with dhfr-ts1, dhfr-ts3 and WT (Gorelova et al., 2017) . Nevertheless, dhfr-ts2 mutants are viable, suggesting that the DHFR-TS1 that remains is able to carry out what folate biosynthesis is required for normal plant function. Additionally, an alternatively spliced DHFR-TS2 lacking the mitochondrial presequence was recently reported (Maniga et al., 2017) that if translated would encode a cytosolic isoform of DHFR-TS2 and so further supports a cytosolic activity of DHFR-TS in A. thaliana. There is thought to be substantial transmembrane traffic in folates and their precursors so that DHF (typically thought to remain in the mitochondrion) might encounter the cytoplasmic DHFR-TS1 (or the putative cytoplasmic variant of DHFR-TS2) and be reduced to THF. THF is already thought to be highly transportable in its monoglutamylated form, and becomes involved in biosyntheses within the vacuole, cytoplasm, plastid and mitochondrion (Hanson and Gregory, 2011) .
Using forward genetics under selection from pyrimethamine, we found a G137D mutation in DHFR-TS1 that provided plants with cross-resistance to other DHFR inhibitors. A similar approach under selection from cycloguanil found a resistant A71V mutation in DHFR-TS2 that did not provide plants with cross-resistance to other inhibitors. These in planta findings could be reconstituted in vitro with recombinant protein. In vitro experiments using recombinant DHFR-TS1 with a G137D mutation showed the protein mutant could continue catalysing DHF reduction in the presence of a broad spectrum of inhibitors. Also consistent with the in planta findings, a recombinant DHFR-TS2 with an A71V mutation only afforded the mutant protein with resistance to cycloguanil in the same in vitro experiments (Figure 6 ). To understand the molecular basis for the different resistance profiles of these mutations, we predicted structural models for DHFR-TS1 and DHFR-TS2 (Figure 4b ). Previous work with a cycloguanilresistant strain of malarial parasite P. falciparum characterised the equivalent Ala to Val mutation in its only copy of DHFR-TS (Sirawaraporn et al., 1993; Yuvaniyama et al., 2003) . Furthermore, the crystal structure of P. falciparum DHFR-TS and enzyme kinetic analyses showed that this change to Val induced a steric clash between the sidechain of the Val and a 2-methyl group of cycloguanil (which is absent in pyrimethamine) without abolishing the activity of PfDHFR-TS (Vanichtanankul et al., 2012) . It is therefore very likely that the equivalent A71V mutation in A. thaliana DHFR-TS2 confers resistance to cycloguanil similarly, that is the Val mutation would prevent cycloguanil binding by clashing with its 2-methyl group, but would not clash in the case of pyrimethamine due to a lack of that methyl group.
The A. thaliana DHFR-TS1 G137D mutant on the other hand, to the best of our knowledge, has not been described before as a mutational hot-spot in DHFR. Interestingly, this mutation aligns to a position (A154) that was previously found to interact with NADPH in Toxoplasma gondii (Sharma et al., 2013) , and also was found not to be strictly conserved, suggesting the opportunity for mutation. The mutation of a residue at the NADPH cofactor binding site implies that this mutation is likely to have an indirect effect on inhibitor binding, as replacement of this small amino acid (Gly) with a larger negatively charged amino acid (Asp) is likely to shift the binding position of the similarly charged NADPH phosphate backbone and result in an altered conformation for the nicotinamide group in the active site. This altered conformation would result in reduced space for the concomitant binding of DHF and significant steric hindrance for bulkier inhibitors based on this substrate. Such a proposed molecular mechanism of resistance is supported by the dramatic reduction in efficiency of DHFR activity in the absence of inhibitors for DHFR-TS1, and the equivalent mutation in DHFR-TS2, and explains the broader resistance of the mutant to herbicidal antimalarial compounds. Furthermore, it is tempting to speculate that although an equivalent mutation in bacteria and protozoa may not have occurred yet, possibly due to the impaired fitness upon the organism, increasing selection pressures from the development of antifolates to combat current resistant strains may result in an equivalent mutation arising in the future.
Dihydrofolate reductase is an important enzyme and a target enzyme for drug design. Plants do not seem to possess monofunctional DHFR enzymes such as those of humans and bacteria, and instead have bifunctional DHFR-TS enzymes like those in protozoa including the malarial parasite P. falciparum. The recent finding that antimalarial compounds exhibit herbicidal qualities suggested that DHFR could represent a new target for herbicidal development. Differences between bifunctional plant or protozoal DHFR-TS enzymes and the mammalian or bacterial DHFRs present opportunities to develop plant-specific DHFR inhibitors. DHFR drug selectivity is already commonplace. The antimicrobial drug trimethoprim, that is often used to treat human bladder infections, strongly favours microbial DHFR (Brogden et al., 1982) . The antimalarial drugs pyrimethamine and cycloguanil similarly do not affect mammalian DHFR . The antimalarial drug WR99210 is also known to target P. falciparum DHFR-TS with higher selectivity than human DHFR (Fidock and Wellems, 1997) . Interestingly, the effectivity of WR99210 is thought to be caused by drug-induced overexpression of human DHFR rather than strong drug affinity for the P. falciparum enzyme (Zhang and Rathod, 2002) . A range of DHFR inhibitors tested against different organisms (i.e. plant, bacterium and yeast) yields LD 50 values that suggest some have a degree of plant DHFR specificity already or an inability for some compounds to penetrate microbes (Table S3) . Although the structure of plant and P. falciparum DHFR-TS are likely to be similar enough to make specific molecules difficult to design, the highest priority for any herbicide targeting DHFR will be to ensure it is non-toxic to humans and soil bacteria. Comparing the crystal structure active site of the human DHFR domain versus the modelled structure of A. thaliana DHFR-TS1 highlights several non-conserved residues. Such differences could offer opportunities for the structure-based rational design of plant-specific DHFR inhibitors with reduced affinity to human DHFR. For example, these differences likely include significant changes in hydrophobicity (with Y81 and N43 of AtDHFR-TS1 substituted with N65 and P27, respectively, in the human DHFR enzyme); steric hindrance (with L48 in the A. thaliana DHFR domain substituted with a bulkier F32 in human DHFR); and changes in electrostatic potential (with a positively charged K39 of AtDHFR-TS1 overlaying with a negatively charged aspartate residue D22 in human DHFR; Figure 7 ). Our findings lay the foundation for the development of highly specific, non-toxic, herbicidal compounds targeted at DHFR-TS, and we predict that resistance to such herbicides could evolve in a manner analogous to resistance seen with the use of anti-infectives and as such may be combated in a similar manner. Future structural characterisation of plant DHFR-TS proteins would undoubtedly aid in the development of such herbicides.
EXPERIMENTAL PROCEDURES Plant materials and genotyping
Experiments were carried out with A. thaliana ecotype Columbia (Col-0), and T-DNA lines obtained from ABRC (SALK lines) or NASC (GABI-Kat lines). To investigate the function of the three A. thaliana DIHYDROFOLATE REDUCTASE-THYMIDYLATE SYNTHASE genes, i.e. DHFR-TS1 (At2g16370), DHFR-TS2 (At4g34570) and DHFR-TS3 (At2g21550), two T-DNA insertion lines per gene were used: SALK_054193 (dhfr-ts1-3), GABI_010G06 (dhfr-ts1-1), SALK_016377 (dhfr-ts2-1), GABI_893C02 (dhfr-ts2-2), SALK_114609 (dhfr-ts3-1) and SALK_013998 (dhfr-ts3-3). Homozygous T-DNA lines were identified using PCR with gene-specific and T-DNA-specific primers (Table S2) , and the position of each T-DNA insert was confirmed by sequencing PCR products. The T-DNA insertion was located in the second exon for dhfr-ts1-3, in the ninth exon for dhfr-ts1-1, at the junction of the first intron and the second exon for dhfr-ts2-1, in the seventh exon for dhfr-ts2-2, in the second exon for dhfr-ts3-1, and in the eighth exon for dhfrts3-3 ( Figure S1b ). The dhfr-ts3 T-DNA line (SALK_144255) displayed pleiotropic phenotypes not segregating with the T-DNA and therefore was not used in this study.
Growth conditions
Pots of 63 9 63 9 59 mm were filled with soil consisting of Irish peat, perlite and vermiculite in a 3:1:1 ratio. A. thaliana seeds were sown on the surface of the pre-wet soil before being placed in the dark at 4°C for at least 3 days to synchronise germination. Following stratification, pots were placed in growth chambers under a 16 h light/8 h dark photoperiod at 22°C and 60% relative humidity. Seven-10-day-old seedlings were transferred to individual pots and grown in the same conditions.
For agar-grown A. thaliana, seeds were surface-sterilised by ethanol or chlorine gas. For ethanol-mediated sterilisation, seeds were mixed in 70% ethanol for 3 min, followed by 1 min in 100% ethanol, then washed with sterile water for 3 min and resuspended in sterile 0.1% agar. For chlorine gas, seeds were placed in 2-ml tubes and sterilised by adding 3 ml 10.2 M hydrochloric acid to 50 ml bleach and leaving them enclosed in a desiccant jar for at least 3 h. Depending on the sterilisation method, seeds were sown on 96-well plates or square Petri dishes by pipetting or ) and dimethylsulphoxide (DMSO; control, when specified). Seeds were stratified and germinated using the aforementioned conditions. All DHFR inhibitors, i.e. cycloguanil, pyrimethamine, methotrexate and trimethoprim were obtained from AK Scientific. Glufosinate ammonium (i.e. phosphinothricin) was purchased from Sigma-Aldrich.
DNA and RNA extraction
For all DNA extractions, leaf tissue was homogenised in a 2-ml tube using a tungsten carbide bead in 500 ll of extraction buffer (250 mM sodium chloride, 25 mM EDTA, 0.5% sodium dodecyl sulphate and 200 mM Tris-HCl, pH 7.5) using a Retsch mixer mill (20 frequency per sec for 30 sec followed by 30 frequency per sec for 30 sec), then centrifuged at 18 000 g for 2 min. Of the supernatant, 300 ll was transferred to a fresh tube, mixed with 300 ll isopropanol and centrifuged at 18 000 g for 5 min. Following centrifugation, the supernatant was removed and the pellet air-dried for at least 20 min then resuspended in 50 ll TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0).
RNA extraction was carried out on WT and dhfr-ts T-DNA insertion lines that were confirmed homozygous. Tissue from 3-week old rosette leaves was ground in liquid nitrogen to a fine powder, transferred to a 2-ml tube and stored at À80°C prior to extraction. To each tube of ground tissue, 250 ll phenol, 500 ll homogenisation buffer (100 mM Tris pH 8.0, 5 mM EDTA, 100 mM sodium chloride, 0.5% sodium dodecyl sulphate) and 5 ll b-mercaptoethanol (pre-warmed to 60°C) was added. After vortexing for 15 min, 250 ll chloroform was added and the tubes mixed by vortex for a further 15 min. The mixture was centrifuged at 13 000 g for 10 min at room temperature. Following centrifugation, 550 ll of the aqueous layer supernatant was transferred to a new tube and 550 ll of phenol:chloroform was added before being mixed by vortex for 10 min and centrifuged again. Of the aqueous layer, 500 ll was transferred to a fresh tube. To precipitate nucleic acids, 50 ll 3 M sodium acetate and 400 ll isopropanol was added, and the mixture was incubated at À80°C for 15 min before it was centrifuged at 13 000 g at 4°C for 30 min. Following centrifugation, the supernatant was removed and tubes dried for 10 min. The pellet was resuspended in 0.5 ml water, and to precipitate RNA, 0.5 ml of 4 M lithium chloride was added, and the tubes incubated at 4°C overnight. The following day, the tubes were centrifuged at top speed at 4°C for 30 min, the pellet was washed in 80% ethanol, air-dried and resuspended in 60 ll water. For each sample, an aliquot of total RNA was run on a 0.8% Tris-borate-EDTA gel to confirm RNA integrity. Prior to reverse transcription, approximately 10 lg of RNA was digested with DNaseI (New England Biolabs, Ipswich, MA, USA) at 37°C for 10 min and RNA recovered using a NucleoSpin RNA clean-up kit (Macherey-Nagel, D€ uren, Germany). For cDNA synthesis, the ProtoScript â II reverse transcriptase (New England Biolabs) was used according to the manufacturer's instructions.
Arabidopsis thaliana EMS mutagenesis and identification of DHFR inhibitor-resistant mutants
Approximately 1 g of A. thaliana seeds (M 0 ) was incubated for 16 h in a glass beaker containing 100 ml water and 250 ll ethyl methanesulfonate (EMS; Sigma-Aldrich, St. Louis, MO, USA). Following incubation, the M 1 seeds (i.e. post-EMS treatment) were rinsed with 4 L of water through a filter paper and dried for 2 days. M 1 seeds were sown on pre-wet soil, stratified and germinated under long-day conditions as described earlier. Following development of the primary shoots, the apical region was cut off to stimulate the emergence of axillary branches. The M 1 plants were grown to full maturity, and the M 2 seeds (i.e. M 2 progeny) were collected and used for screening.
For the screening of DHFR inhibitors-resistant A. thaliana mutants, M 2 seeds were sterilised with chlorine gas and germinated on MS agar square Petri dishes supplemented with 15 lg ml À1 pyrimethamine or cycloguanil, i.e. two known DHFR inhibitors used as antimalarial drugs. Seedlings that were drug resistant were transferred to soil, and the M 3 progeny was tested for heritability of resistance to the corresponding compounds. Upon confirmation of pyrimethamine and cycloguanil resistance in the rescued M 3 seedlings, DNA was extracted and all three A. thaliana DHFR-TS genes were PCR amplified and each PCR product directly sequenced to identify lesions ( Figure S1c ).
Mutant DHFR transgenes with dhfr-ts1-4 and dhfr-ts2-3 lesions Sequencing the DHFR-TS1, DHFR-TS2 and DHFR-TS3 genes from antifolate-resistant M 3 plants revealed a G137D mutation and a A71V mutation in the predicted protein sequences of DHFR-TS1 and DHFR-TS2, respectively ( Figure S1a ). To determine whether the G137D mutation (called dhfr-ts1-4) and the A71V mutation (called dhfr-ts2-3) conferred resistance to pyrimethamine and cycloguanil, respectively, we transformed the dhfr-ts1-4 and dhfrts2-3 genes into WT. The genomic sequence for DHFR-TS1 and DHFR-TS2 was PCR amplified from these mutants (Table S2 ) using the Q5 high-fidelity DNA polymerase (New England Biolabs) and the PCR reaction purified (Qiagen, Hilden, Germany). These genomic regions included 1245 bp and 1093 bp of sequence upstream of the annotated transcription start site of DHFR-TS1 and DHFR-TS2, respectively. The purified PCR fragments were A-tailed using Taq DNA polymerase, ligated into pGEM-T Easy (Promega) and subsequently transformed in E. coli TOP10 competent cells. Both pGEM-dhfr-ts1-4 and pGEM-dhfr-ts2-3 were excised from pGEM-T Easy in two steps. The first digestion with SacII linearised the plasmid. The SacII overhanging ends were filled by Klenow and the DNA fragments were then subjected to digestion with SpeI that also cleaves within pGEM-T Easy and liberated a sticky-blunt fragment. The DHFR-TS fragments were separated from pGEM-T Easy by gel electrophoresis, and the 4.2-or 4.5-kb DHFR-TS1 and DHFR-TS2 gene fragments were excised from the gel and purified. The DNA fragments were subcloned into the plant binary vector pSLJ755I5 (Jones et al., 1992) that had been linearised with Eco53kI and digested with XbaI to create compatible ends for ligation to a SpeI-blunt fragment. After confirming successful ligation, the pSLJ755I5-dhfr constructs in E. coli TOP10 competent cells were tri-parental mated into Agrobacterium tumefaciens LBA4404 with E. coli DH5a (pRK2013) as helper. WT A. thaliana was transformed by in planta transformation essentially as described by Bechtold et al. (1993) . The first generation of transformants (T 1 ) was selected for Basta resistance, and the T 2 was germinated on Basta 10 lg ml À1 plates to determine the segregation ratio of Basta resistance as an indication of T-DNA locus number. Two DHFR-TS1 G137D lines and one DHFR-TS2 A71V line were selected as they displayed 3:1 segregation ratios for Basta resistance to Basta susceptibility suggesting a single and stable insertion locus. Homozygous T 3 lines were identified and germinated on DHFR inhibitors with WT (control) to confirm antifolate resistance. An additional DHFR-TS2 A71V line that displayed Mendelian segregation ratios at two loci was used for a co-segregation analysis to further correlate the causative lesion with antifolate resistance. This was achieved by germinating the transgenic line on cycloguanil and Basta plates, transplanting resistant seedlings from the cycloguanil plate to a Basta plate and vice versa, to confirm that the transgene was indeed responsible for drug resistance. To track the dhfr-ts1-4 and dhfr-ts2-3 mutations, a derived cleaved amplified polymorphic sequences (dCAPS) assay was developed using dCAPS Finder 2.0 (Neff et al., 2002) . The primer pair designed to follow the dhfr-ts1-4 mutation amplifies a 238-bp PCR fragment. WT DHFR-TS1 is cleaved into 206 and 32 bp when digested with BstEII, whereas the dhfr-ts1-4 product is not cleaved by BstEII. The primers designed for the dhfr-ts2-3 mutation amplify a 287-bp fragment that is cleaved into 260 and 27 bp by PstI for the WT DHFR-TS2 product but remain undigested for the dhfr-ts2-3 product (Table S2) .
Genetic crosses and phenotypical analysis
Three dhfr-ts single mutants were crossed to obtain all double mutant combinations in the homozygous state if possible or heterozygous if not. For each cross, both the F 1 and F 2 progeny were genotyped to confirm the heterozygosity or homozygosity of the T-DNA insertions and to identify double mutants. For each genotype obtained, 20 siliques were dissected and seeds (normal and aborted) were counted to provide an average of total seeds and a percentage of defective embryos per silique. Siliques were visualised using the SZX7 Olympus microscope and imaged with analySIS getIT (Olympus, Tokyo, Japan).
Each genotype in a dhfr-ts2-1 heterozygous state background displayed siliques with a high percentage of defective ovules. This might indicate an effect of T-DNA insertion-associated chromosomal rearrangement in the dhfr-ts2-1 single mutant that was used for genetic crosses. As chromosomal rearrangements are often linked to defective gametes (Clark and Krysan, 2010) , we sought to test the pollen viability of a series of dhfrts2-1 heterozygous backgrounds. Freshly open flowers were collected and pollen grains were stained on microscope slides with Alexander staining solution (Alexander, 1969) for 2 h at 50°C. Pollen grains were visualised using the BX51 Olympus microscope at 209 magnification, imaged with analySIS getIT (Olympus) and counted from five independent quadrants on the slides. Additionally, from the same dhfr-ts2-1 heterozygous backgrounds abovementioned, 20 siliques were collected, imaged and their length determined using ImageJ.
Pyrimethamine and cycloguanil resistant M 3 mutants were backcrossed to WT and the F 1 seeds were germinated on antifolate-supplemented media to determine if the mutations conferring drug resistance were dominant or recessive. Antifolate-resistant F 1 seedlings were further backcrossed to the WT to remove unlinked, background EMS mutations. The F 1 generation resulting from the second backcross was grown on soil and the F 2 progeny was germinated on antifolate-supplemented plates to determine resistance to sensitivity ratios.
Targeting assays for fluorescence-tagged DHFR-TS1 and DHFR-TS2
Full-length DHFR-TS2 cDNA was amplified from WT cDNA using gene-specific primers flanked by Gateway recombination cassettes and cloned into pDONR201. Full-length DHFR-TS1 cDNA cloned in pUni51 was obtained from ABRC (clone ID: U11710), amplified using gene-specific primers flanked by Gateway recombination cassettes (Table S2 ) and cloned into pDONR201. LR reactions were carried out into C-terminal GFP fusion vectors for GFP localisation (Carrie et al., 2009) . Biolistic co-transformation of the C-GFP and a mitochondrial-Cherry vector (Nelson et al., 2007) was carried out on 5-day-old A. thaliana (Col-0) cell suspensions as previously described (Carrie et al., 2009) . Briefly, 5 lg of GFP and mitochondrial-Cherry plasmids were co-precipitated onto gold particles and bombarded using the PDS-1000/He biolistic transformation system (Bio-Rad, Hercules, CA, USA). GFP and mito-Cherry expression was visualised and captured at 1009 magnification using the BX61 Olympus microscope at 460/480 nm (GFP) and 570-625 nm (mtCherry). Images were processed using the Olympus Xcellence imaging software.
Mitochondrial isolation and protein uptake assays
Mitochondria were isolated from 14-day-old, plate-grown Col-0 A. thaliana as previously described (Murcha and Whelan, 2015) , and import assays performed as described by Duncan et al. (2015) . Synthesis of radiolabelled DHFR-TS1, DHFR-TS2 and AOX1 (Whelan et al., 1993) was carried out using the rabbit reticulocyte TNT in vitro transcription/translation kit (Promega, Madison, WI, USA) under the T7 promoter in pDest14. Briefly, 50 lg of freshly isolated mitochondria was incubated with radiolabelled precursor protein in a buffer that supports protein uptake at 26°C for 20 min. Following this, the reaction was placed on ice and, to half, Proteinase K was added at a concentration of 0.4 lg ml À1 to digest any non-imported protein, or protein bound to the outer membrane. Assays were also carried out in the presence of valinomycin, an ionophore that dissipates the mitochondrial membrane potential and prevents import across the inner membrane. The mitochondria were washed and isolated followed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis. The gel was dried and exposed to phosphor-imaging plate for 48 h prior to detection.
Growth inhibition assays for LD 50 determination
To test the activity and specificity of DHFR inhibitors against a range of organisms, growth inhibition experiments were performed in A. thaliana (Col-0), E. coli TOP10 cells and Saccharomyces cerevisiae strain BJ5464. The DHFR-inhibiting drugs cycloguanil, pyrimethamine, trimethoprim and methotrexate were tested against all selected organisms. All compounds were prepared in DMSO. A. thaliana growth inhibition and quantification were carried out as described in Corral et al. (2017a) . For microbial assays, E. coli and S. cerevisiae cells were grown in Luria-Bertani (LB) or Yeast Extract-Peptone-Dextrose (YPD) broth, respectively, until near saturation, and subsequently diluted in growth media to an OD 600 of 0.1. The bacterial and yeast cells were then transferred to 96-well plates supplemented with the tested compounds at different ranges of concentrations, grown at 37°C or 30°C for 16 h, respectively. For each well, the OD 600 was measured using the POLARstar OPTIMA plate reader spectrophotometer (BMG LAB-TECH, Ortenberg, Germany) for LD 50 determination of the compounds using GraFit Data Analysis Software.
Structural modelling
The homology models of A. thaliana DHFR-TS1 and DHFR-TS2 were created ab initio based on the structure of the bifunctional DHFR-TS enzyme from B. bovis (PDB 3K2H; Begley et al., 2011) , using the I-TASSER server (Zhang, 2008) . The substrates DHF and the cofactor NADPH were modelled into the active site through alignment to Cryptosporidium hominis DHFR-TS (PDB 1QZF; O'Neil et al., 2003) in PyMOL, and mutations that resulted in resistance to pyrimethamine or cycloguanil were modelled with favourable rotamers using COOT (Emsley and Cowtan, 2004) .
Cloning of DHFR-TS1 and DHFR-TS2 synthetic genes and site-directed mutagenesis Escherichia coli codon-optimised genes of A. thaliana DHFR-TS1 and DHFR-TS2 were synthesized at GeneArt (ThermoFisher Scientific, Waltham, MA, USA). Both synthetic genes encoded a Tobacco Etch Virus (TEV) cleavage motif (ENLYFQ) immediately upstream of the encoded DHFR-TS protein. The sequence of the synthetic DHFR-TS1 and DHFR-TS2 genes was excised from its host plasmid pMA-T with BamHI and SalI, and sub-cloned into pQE-30 (Qiagen), which encodes an N-terminal 6-His tag. This plasmid was transformed into E. coli SHuffle T7 Express (New England Biolabs) competent cells that also carried the pREP4 repressor plasmid (Qiagen). To determine whether the G137D mutation in DHFR-TS1 and the A71V mutation in DHFR-TS2 that conferred antifolate resistance in vivo had effects on the activity of both enzymes in vitro, the mutations were inserted in the respective synthetic genes using site-directed mutagenesis. An equivalent G137D mutation in DHFR-TS2 and A71V mutation in DHFR-TS1 were also prepared, which resulted in a G181D mutation in DHFR-TS2 and an A27V mutation in DHFR-TS1 respectively, by sequence homology. Synthetic DHFR-TS1 and DHFR-TS2 cloned in pQE-30 were purified and used as template for PCR using overlapping primers with the desired mutations (Table S2) with DMSO (5%) added to the reaction. PCR products were purified (QIAquick PCR purification kit, Qiagen, Hilden, Germany), digested with DpnI overnight to cleave the methylated parental plasmid used as template, and transformed into pREP4-carrying SHuffle T7 Express cells. All mutations were confirmed by sequencing analyses using primers flanking the insert of interest. Upon purification of the synthetic DHFR-TS proteins, it was found that DHFR-TS2 was insoluble most likely due to the presence of a mitochondrial presequence. To remove the putative signal peptide, we designed 5 0 -phosphorylated primers (Table S2 ) that allowed deletion of this predicted signal sequence by PCR. The PCR reactions were digested with DpnI to remove template and the linear PCR product was circularised by ligation before transformation into SHuffle T7 Express competent cells.
Recombinant DHFR-TS production in Escherichia coli, purification and assays All WT and mutant recombinant DHFR-TS proteins were expressed in the E. coli strain SHuffle T7 Express containing pREP4. An overnight culture of the transformed bacteria was grown from a glycerol stock at 30°C in LB medium containing 100 lg ml À1 ampicillin and 25 lg ml À1 kanamycin. From this overnight culture, 20 ml was used to inoculate 1 L of LB medium and the resultant culture grown at 30°C until an OD 600 of approximately 0.8. Protein expression was then induced by addition of isopropyl b-D-1-thiogalactopyranoside to 0.5 mM and shaking overnight at 16°C. Bacteria were pelleted by centrifugation for 15 min at 3800 g at 4°C.
To purify recombinant DHFR-TS proteins, the cell pellets were resuspended in 10 ml lysis buffer (50 mM Tris-HCl, 100 mM sodium chloride, 0.1% Triton X-100, pH 8.0) and lysed by sonication for 15 min with a 3.3-sec pulse (amplitude 38%) followed by a 9.9-sec pause. The lysate was centrifuged for 15 min at 12 000 g and 4°C. The supernatant containing the 6-His-tagged recombinant DHFR-TS protein was incubated overnight at 4°C in Profinity TM IMAC uncharged resins (Bio-Rad) charged with Ni 2+ . The beads were then loaded onto a Poly-Prep â Chromatography Column (Bio-Rad) and washed with 70 ml washing buffer (20 mM Tris pH 8.0, 150 mM sodium chloride). The protein was eluted with 5 ml of washing buffer containing 75 mM imidazole followed by washing buffer with 300 mM imidazole. An Amicon â Ultra-15 Centrifugal Filter Devices (Millipore) was used to concentrate the pooled 75 and 300 mM imidazole fractions to a volume of 2 ml by centrifugation at 1800 g and 4°C. The sample was further purified by cleavage of the 6-His tag from the protein at its TEV cleavage site with TEV protease and repeating the IMAC Ni 2+ affinity purification. The sample was then dialysed overnight at 4°C in washing buffer and 1 mM dithiothreitol using dialysis tubing containing 0.04 mg TEV protease per 1 mg protein and 1 mM dithiothreitol. The sample was then loaded onto a chromatography column containing nickel-charged IMAC beads. The flow-through and wash fraction were pooled and concentrated, and the solution was exchanged with size exclusion buffer (50 mM Tris pH 8.0, 150 mM sodium chloride). Recombinant DHFR-TS was further purified by size exclusion using a HiLoad â 16/600 Superdex â 200 pg column (Sigma-Aldrich). The concentration of recombinant DHFR-TS was determined spectrophotometrically using the specific molar extinction coefficient of the proteins calculated using ProtParam (http://web.expasy.org/protparam/). The molar extinction coefficient (at 280 nm) of DHFR-TS1 was 65 485 M À1 cm À1 , and that of DHFR-TS2 for which the predicted mitochondrial presequence was deleted was 70 985 M À1 cm À1 (there was no difference between WT and mutant enzymes).
The DHFR activity of the WT and mutant DHFR-TS proteins was determined based on the ability of the enzyme to oxidise NADPH during the conversion of DHF to THF (Figure 1a ), which can be measured by monitoring the decrease of OD 340 while the reaction occurs. The assay buffer consisted of 50 mM 4-(2-hydroxyethyl) piperazine-1-ethanesulphonic acid (HEPES, pH 7.4) and 100 mM potassium chloride (Gibson et al., 2016) . NADPH (Sigma-Aldrich) stock solutions were prepared in 0.01 M sodium hydroxide at a concentration of 20 mM, whereas DHF (Sigma-Aldrich) stock solutions were prepared in 0.1 M sodium hydroxide at 5 mM in amber tubes as the compound is light-sensitive. The DHFR inhibitors pyrimethamine and cycloguanil stock solutions were prepared in DMSO at 100 mM. The NADPH standard curve and all enzymatic reactions were performed in 96-well clear V-bottom plates (Axygen, Union City, CA, USA) in final volumes of 200 ll per well, and the absorbance at 340 nm was followed using the POLARstar OPTIMA plate reader spectrophotometer (BMG LABTECH). To generate the standard curve, NADPH was diluted in assay buffer at 0.5 mM, added into a series of wells to produce 0, 10, 20, 30, 40, 60 and 100 nmol well À1 NADPH (volume adjusted to 200 ll well
À1
with assay buffer), and OD 340 was measured ( Figure S5 ). Prior to enzymatic assays, a 40-fold dilution of NADPH, a 15-fold dilution of DHF and a 1000-fold dilution of the DHFR inhibitors were prepared in assay buffer and solutions were kept on ice. All DHFR-TS proteins were resuspended in assay buffer at a concentration of 0.1 mg ml À1 and kept on ice. DHFR activity was determined by pre-incubating DHFR-TS with 100 lM NADPH in assay buffer for 2 min at room temperature in the presence or absence of DHFR inhibitors. To initiate the reaction, 100 lM DHF was added and OD 340 was immediately measured every 60 sec for 40 min (Figure S6) . For all curves obtained, two time points were chosen, and their corresponding OD 340 values were subtracted and used to determine the amount of NADPH generated during the reaction time using the standard curve. Values of 'no enzyme' controls consisting only of NADPH, DHF and assay buffer in the presence or absence of inhibitors were subtracted from their corresponding sample readings. The DHFR activity of all samples was calculated as followed: DHFR activity = amount NADPH /(reaction time 9 total protein amount) expressed in nmol min À1 mg À1 or mU mg
. One unit of DHFR is defined as the amount of enzyme that oxidises 1 lmol of NADPH per min at room temperature.
Phylogenetic analysis
Orthologues to A. thaliana DHFR-TS1, DHFR-TS2 and DHFR-TS3 were identified by sequence homology using BLASTn with default settings in Phytozome v12.1 (Goodstein et al., 2012) . Selected species include P. patens, S. moellendorffii, Z. mays, Oryza sativa, Solanum tuberosum, Vitis vinifera, Eucalyptus grandis, Brassica rapa, Capsella rubella, Medicago truncatula, Glycine max, Ricinus communis, Populus trichocarpa, Chlamydomonas reinhardtii. All identified orthologues were manually curated to include only proteins with a similarity threshold below 1e-40. Alignments were performed using Clustal, and the phylogenetic tree was analyzed and drawn using MEGA 7 (Kumar et al., 2016) using the maximum likelihood tree method and the Jones-Thornton-Taylor model after 1000 replications. Protein localisation predictions were carried out using TargetP (Emanuelsson et al., 2007) .
ACCESSION NUMBERS
The Arabidopsis Gene Index code for DHFR-TS1 is At2g16370, DHFR-TS2 is At4g34570 and DHFR-TS3 is At2g21550. Protein Data Bank codes for data used in DHFR figures are: E. coli 4RGC, Homo sapiens 4M6K, P. falciparum 4DPD, B. bovis 3K2H and C. hominis PDB 1QZF.
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